The Claim
In patients with mild Alzheimer’s disease, intravenous administration of laromestrocel (25–100 million cells monthly for 4 months) is associated with a 48.4% slower rate of whole-brain atrophy over 39 weeks compared to placebo, as measured by volumetric MRI.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In people with mild Alzheimer’s disease, monthly intravenous infusions of laromestrocel for four months are associated with a 48.4% reduction in the rate of brain shrinkage over 39 weeks compared to no treatment, as measured by MRI scans.
See the scientific wording
In patients with mild Alzheimer’s disease, intravenous administration of laromestrocel (25–100 million cells monthly for 4 months) is associated with a 48.4% slower rate of whole-brain atrophy over 39 weeks compared to placebo, as measured by volumetric MRI, suggesting a potential neuroprotective effect on brain structure.
Infused stem cells release molecules that stop a key blood vessel receptor from breaking apart, which keeps blood vessels in the brain strong and reduces inflammation, preventing brain tissue from shrinking.
What the research says
1 studyIn a small study, people with early Alzheimer’s who got monthly stem cell infusions had nearly half as much brain shrinkage as those who got dummy treatments, suggesting the therapy might help protect the brain.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.